OverviewSuggest Edit

ImpriMed is a company engaged in the development of precision cancer treatment for canines. It provides personalized drug testing services. The Company studies patients' drug responses and helps veterinary oncologists to prescribe a final treatment. In addition, it collects gene and cell information from pets' cancer cells and organizes them in a database. 

HQPalo Alto, US


ImpriMed is headquartered in
Palo Alto, United States

Location Map

Latest Updates

Employees (est.) (Mar 2020)11

Key People/Management at ImpriMed

Sungwon Lim

Sungwon Lim

Founder CEO
Hye Ryeon Lee

Hye Ryeon Lee

Founder COO
Jamin Koo

Jamin Koo

Mainak Chowdhury

Mainak Chowdhury

Co-Founder Engineer
Show more

ImpriMed Office Locations

ImpriMed has offices in Palo Alto and Seoul
Palo Alto, US (HQ)
2627 Hanover Street
Seoul, KR
50, Arisu-ro 50-gil, 208-dong 2704-ho Gangdong-gu
Show all (2)

ImpriMed Financials and Metrics

Summary Metrics

Founding Date


ImpriMed total Funding

$4 m

ImpriMed latest funding size

$3.70 m

Time since last funding

a year ago

ImpriMed investors

ImpriMed's latest funding round in April 2019 was reported to be $3.7 m. In total, ImpriMed has raised $4 m
Show all financial metrics

ImpriMed Online and Social Media Presence

Embed Graph

ImpriMed Frequently Asked Questions

  • When was ImpriMed founded?

    ImpriMed was founded in 2017.

  • Who are ImpriMed key executives?

    ImpriMed's key executives are Sungwon Lim, Hye Ryeon Lee and Jamin Koo.

  • How many employees does ImpriMed have?

    ImpriMed has 11 employees.

  • Who are ImpriMed competitors?

    Competitors of ImpriMed include Small Door, Vetted PetCare and Banfield Pet Hospital.

  • Where is ImpriMed headquarters?

    ImpriMed headquarters is located at 2627 Hanover Street, Palo Alto.

  • Where are ImpriMed offices?

    ImpriMed has offices in Palo Alto and Seoul.

  • How many offices does ImpriMed have?

    ImpriMed has 2 offices.